GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$23.48-4.40%
Price as of Jul 20, 2026
GLUE valuation
Monte Rosa Therapeutics, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 179.72x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.80x
- Price / sales
- 46.18x
- Price / cash flow
- -135.17x
Enterprise value
- Enterprise value
- $1.4B
- EV / sales
- 31.58x
- EV / EBITDA
- -10.98x
- EV / EBIT
- -9.15x
- Market cap
- $2.0B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.